Protocol paper for Mobilise-D scoping review published

Walking limitations are debilitating symptoms in many chronic diseases, and are highly related to quality of life, fall risk, and economic burden. Unsurprisingly, walking ability is a common target of pharmacological or behavioural intervention. Thanks to advances in wearable sensor technologies, it is now possible to objectively monitor how, and how much, patients walk in…

Walking in the lab and a real-world environment with Multiple Sclerosis

Our colleagues from Tel Aviv, the TASMC Mobilisers, studied the quality of walking of people with multiple sclerosis and healthy controls in two environments: a) a well-structured laboratory setting and b) during real-life, everyday walking using 24/7 monitoring.  During every-day walking, the patients took fewer steps, they walked more slowly, and the quality of their…

New publication on gait variability in Huntington’s disease

The expertise of our Mobilisers goes far beyond the Mobilise-D patient groups. Ultimately our findings should benefit anyone with mobility challenges, such as people suffering from Huntington’s Disease. Heiko Gaßner and colleagues explain more in their paper investigating gait variability as digital biomarkers of severity in Huntington’s disease. In this study, characteristic features of gait…